酷派集團(02369.HK)美國新產品上市時間或延至第三季
酷派集團(02369.HK)公布,由於疫情的持續影響,集團預計原計劃於今年第二季度在美國的新產品上市時間或推後至第三季度。同時,受疫情影響下新產品推出的延後及營銷支出的增加,將為今年上半年的經營及業績帶來挑戰。
此外,集團計劃將高性價比的5G手機產品引入日本市場,並正與相關客戶展開密切溝通及產品開發和測試工作;亦計劃在近期於中國市場陸續推出三個型號的新智能手機產品。
今年首四個月,集團營業收入與去年同期基本持平,主要得益主要業務貢獻地美國區域的銷售同比有所增長,而東南亞及南亞市場卻受年初的疫情影響而導致營業收入下滑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.